SCHEMBL30036680

SCHEMBL30036680

NC(=O)c1cc2c(cn1)COC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 2/20 0.40
LCK P06239 1/20 0.39
PRF1 P14222 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
TSHR P16473 1/20 0.37
MC4R P32245 1/20 0.37
ADRA1A P35348 1/20 0.37
MC3R P41968 1/20 0.37
KMT2A Q03164 1/20 0.36
XIAP P98170 3/20 0.34
BIRC2 Q13490 3/20 0.34
LMNA P02545 2/20 0.34
NNMT P40261 2/20 0.33
CYP11B2 P19099 1/20 0.32
POLB P06746 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
GSK3B P49841 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19641430 1.00 SIRT6 (0.40) SIRT6LCKPRF1ADORA3TSHR
SCHEMBL30587474 0.88 XIAP (0.33) SIRT6LCKPRF1XIAPBIRC2
SCHEMBL16506549 0.83 KDM4E (0.43) TSHRKMT2AHTTSMN1; SMN2
SCHEMBL16516076 0.81 XIAP (0.34) SIRT6XIAPBIRC2SMN1; SMN2
SCHEMBL16521060 0.81 XIAP (0.34) XIAPBIRC2SMN1; SMN2RIPK1
SCHEMBL29875709 0.78 LCK (0.35) SIRT6LCKPRF1ADORA3TSHR
SCHEMBL18754398 0.77 RIPK1 (0.34) KMT2AXIAPBIRC2POLBRIPK1
SCHEMBL18248727 0.76 NOS3 (0.52) SIRT6LCKADORA3TSHRMC4R
SCHEMBL30334331 0.74 SIRT6 (0.40) SIRT6LCKPRF1ADORA3TSHR
SCHEMBL3324562 0.74 GABRA1 (0.54) KMT2ALMNAPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 EP claimed
EP-3317269-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2022-09-21 EP claimed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 US disclosed
CN-111269221-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2023-09-26 CN disclosed
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-11-03 US disclosed
EP-3317269-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 SIRT6 2689/4885LCK 4712/4885PRF1 1667/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 SIRT6 2689/4885LCK 4712/4885PRF1 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.